The below Parliamentary question was asked by Ruth Cadbury on 2016-01-12.
To ask the Secretary of State for Health, what steps his Department took to publicise the recent NHS Mandate Consultation.
George Freeman
I refer the hon. Member to the answer I gave to the hon. Member for High Peak (Andrew Bingham) on 2 December 2015 to Question 18482.
“
The below Parliamentary question was asked by Ben Howlett on 2016-01-12.
To ask the Secretary of State for Health, what estimate he has made of the number of people in England accessing HIV Pre-Exposure Prophylaxis through private provision.
Jane Ellison
NHS England is working with local authorities, clinicians, patient representatives and Public Health England to consider the clinical and cost effectiveness of providing pre-exposure prophylaxis (PrEP) to at-risk groups to prevent them acquiring HIV. The PrEP clinical policy proposition is one of many going through NHS England’s 2016/17 prioritisation round.
In July 2015 NHS England approved a significant new investment in a ‘Treatment as Prevention’ programme to help reduce transmissions from persons known to be HIV positive.
We have made no estimates of the number of people accessing PrEP through private provision.
The below Parliamentary question was asked by Ben Howlett on 2016-01-12.
To ask the Secretary of State for Health, when HIV Pre-Exposure Prophylaxis will be made available on the NHS to men who have sex with men.
Jane Ellison
NHS England is working with local authorities, clinicians, patient representatives and Public Health England to consider the clinical and cost effectiveness of providing pre-exposure prophylaxis (PrEP) to at-risk groups to prevent them acquiring HIV. The PrEP clinical policy proposition is one of many going through NHS England’s 2016/17 prioritisation round.
In July 2015 NHS England approved a significant new investment in a ‘Treatment as Prevention’ programme to help reduce transmissions from persons known to be HIV positive.
We have made no estimates of the number of people accessing PrEP through private provision.
The below Parliamentary question was asked by Martyn Day on 2016-01-12.
To ask the Secretary of State for Health, what assessment he has made of the potential role of technology in reducing aseptic pharmaceutical medication error.
George Freeman
Where appropriate, automation has a role to play in ensuring consistent output from aseptic compounding and increased production capacity. It may also provide additional protection against microbiological contamination by use of ‘closed systems’ of manufacture.
Licensed specials manufacturers may consider automation as an appropriate solution for their product range and capacity. In these cases, Medicines and Healthcare products Regulatory Agency inspections assess whether the process design, validation, personnel, training and procedures relating to the automated system comply with the requirements of Good Manufacturing Practice.
The below Parliamentary question was asked by Andrew Gwynne on 2016-01-12.
To ask the Secretary of State for Health, whether his Department has a policy on standardising the dose branding of aseptic pharmaceutical products across all health trusts.
George Freeman
The Medicines and Healthcare products Regulatory Agency is working with other groups to promote the risk-reducing benefits of dose banding.
NHS England, through its Medicines Optimisation Clinical Reference Group work programme, is working with key stakeholders to identify/agree national standard dose bands for chemotherapy. A national Commissioning for Quality and Innovation goal has been agreed to support the implementation of the dose bands during 2017-18.
The below Parliamentary question was asked by Andrew Gwynne on 2016-01-12.
To ask the Secretary of State for Health, what assessment he has made of the level of aseptic pharmaceutical medication error within the NHS.
George Freeman
Neither the Department nor NHS England has made any such assessment.
The below Parliamentary question was asked by Andrew Gwynne on 2016-01-12.
To ask the Secretary of State for Health, what steps he is taking to reduce errors in the dispensing of aseptic pharmaceutical products.
George Freeman
The manufacturing process for aseptic pharmaceutical products by licensed Specials manufacturers is subject to Good Manufacturing Practice and Good Pharmacovigilance Practice – both of which are monitored by the Medicines and Healthcare products Regulatory Agency.
Aseptic compounding in pharmacies and health clinics under the section 10 exemption of the Medicines Act 1968 is carried out under the supervision of a pharmacist and is subject to periodic audits by National Health Service quality assurance pharmacists.
The below Parliamentary question was asked by Jim Shannon on 2016-01-12.
To ask the Secretary of State for Health, if he will request that NICE work with the manufacturers of nivolumab to ensure patients with lung cancer can access that medicine at the earliest opportunity.
George Freeman
No such assessment has been made. The National Institute for Health and Care Excellence (NICE) is currently appraising nivolumab (Opdivo) for squamous non-small cell lung cancer and has not yet issued its final guidance.
In developing its technology appraisal guidance, NICE works closely with stakeholders, including manufacturers. NICE’s consultation on its draft guidance closed on 19 January 2016.
In the absence of NICE guidance, it is for commissioners to make funding decisions based on the available evidence.
The below Parliamentary question was asked by Jim Shannon on 2016-01-12.
To ask the Secretary of State for Health, how many patients are receiving nivolumab for locally advanced or metastatic squamous non-small cell lung cancer in (a) England and (b) Strangford; and when NICE plans to complete its appraisal of that drug.
George Freeman
NHS England has advised that it understands that the manufacturer of nivolumab (Opdivo), Bristol-Myers Squibb, received 73 registrations for nivolumab for locally advanced or metastatic squamous non-small cell lung cancer through the Early Access to Medicines Scheme before the scientific opinion expired in July 2015. A geographical breakdown of this figure is not available.
NHS England does not currently fund nivolumab for metastatic squamous non-small cell lung cancer and has advised that its funding position will be determined by the National Institute for Health and Care Excellence’s final technology appraisal guidance which is expected in May 2016. Further information is available at:
www.nice.org.uk/guidance/indevelopment/gid-tag506
“
The below Parliamentary question was asked by Jim Shannon on 2016-01-12.
To ask the Secretary of State for Health, what assessment he has made of the effect of the negative interim NICE Appraisal Committee Decision on nivolumab for squamous non-small cell lung cancer on patients.
George Freeman
No such assessment has been made. The National Institute for Health and Care Excellence (NICE) is currently appraising nivolumab (Opdivo) for squamous non-small cell lung cancer and has not yet issued its final guidance.
In developing its technology appraisal guidance, NICE works closely with stakeholders, including manufacturers. NICE’s consultation on its draft guidance closed on 19 January 2016.
In the absence of NICE guidance, it is for commissioners to make funding decisions based on the available evidence.